Simplified, scalable, and flexible interventional tool to collect patient-reported outcome measures and clinician-reported outcomes beyond the standard of care DURHAM, N.C. , Aug.
21, 2024 /PRNewswire/ -- Real-world evidence (RWE) leader, Target RWE, today announced its new patient-centric platform engageTM - utilized by both patients and study sites to seamlessly capture digital, protocol-specific patient-reported outcome (PRO) measures and clinician-reported outcomes (ClinROs) in the real world. "We are excited to launch engageTM which will be instrumental in supporting our ongoing strategic partnership with the American Association of the Study of Liver Disease (AASLD) and their Cirrhosis Quality Collaborative (CQC) initiatives," said Target RWE Chief Medical Officer Michael W. Fried , MD, FAASLD.
"Initial deployments of our new platform have already demonstrated improved patient adherence and increased completion rates of patient-reported outcomes among patients with cirrhosis in our TARGET-LIVER DISEASE registry." Developed to empower patients to actively participate in Target RWE registries, engageTM is supported by highly engaged study sites across the U.S.
to streamline PRO measure data collection beyond the standard of care. The proprietary platform allows study sites to digitally capture patient consent forms, integrate ClinROs into workflows, and provide patient compensation via Paypal and/or Venmo for eligible completed milestones. "Today's announcement represents.